BlackRock Fund Advisors’s Stemline Therapeutics, Inc. STML Stock Holding History

BlackRock Fund Advisors’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	$5.96M	Buy	556,567 +85,512	+18%	+$1.03M	﹤0.01%	2850
2016 Q3	$5.1M	Buy	471,055 +33,039	+8%	+$269K	﹤0.01%	2834
2016 Q2	$2.96M	Buy	438,016 +31,748	+8%	+$200K	﹤0.01%	3078
2016 Q1	$1.89M	Buy	406,268 +1,724	+0.4%	+$8.42K	﹤0.01%	3093
2015 Q4	$2.55M	Buy	404,544 +12,719	+3%	+$103K	﹤0.01%	3090
2015 Q3	$3.46M	Sell	391,825 -4,692	-1%	-$49.2K	﹤0.01%	2970
2015 Q2	$4.67M	Sell	396,517 -15,726	-4%	-$218K	﹤0.01%	2964
2015 Q1	$5.96M	Buy	412,243 +82,989	+25%	+$1.27M	﹤0.01%	2742
2014 Q4	$5.62M	Buy	329,254 +55,556	+20%	+$801K	﹤0.01%	2808
2014 Q3	$3.41M	Sell	273,698 -11,411	-4%	-$140K	﹤0.01%	2964
2014 Q2	$4.18M	Buy	285,109 +13,388	+5%	+$205K	﹤0.01%	2935
2014 Q1	$5.53M	Buy	271,721 +9,008	+3%	+$219K	﹤0.01%	2764
2013 Q4	$5.15M	Buy	262,713 +3,091	+1%	+$82.5K	﹤0.01%	2811
2013 Q3	$11.8M	Buy	259,622 +30,529	+13%	+$996K	﹤0.01%	2259
2013 Q2	$5.46M	Buy	+229,093	New	+$3.65M	﹤0.01%	2630

Other funds holding STML

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

VMI

VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock Fund Advisors's STML Position: Q4 2016 in Review

BlackRock Fund Advisors increased its Stemline Therapeutics, Inc. (STML) stake by 18% in Q4 2016, buying an estimated $1.03M and bringing the position to 556,567 shares worth $5.96M. The position accounts for ﹤0.01% of the portfolio, ranked #2850.

BlackRock Fund Advisors first reported a position in STML in Q2 2013 and has held it in 15 quarters since. The position peaked at $11.8M in Q3 2013. 74 funds tracked by Wall St. Rank hold STML as of Q4 2016.

BlackRock Fund Advisors held 556,567 shares of Stemline Therapeutics, Inc. worth $5.96M as of Q4 2016.
BlackRock Fund Advisors bought 85,512 Stemline Therapeutics, Inc. shares in Q4 2016, an estimated $1.03M.
Stemline Therapeutics, Inc. made up ﹤0.01% of BlackRock Fund Advisors's portfolio in Q4 2016, its #2850 holding.
BlackRock Fund Advisors first reported a position in Stemline Therapeutics, Inc. in Q2 2013 and has held it in 15 quarters since.
BlackRock Fund Advisors's Stemline Therapeutics, Inc. position peaked at $11.8M in Q3 2013.
74 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2016.

Based on BlackRock Fund Advisors's 13F filing for Q4 2016, filed 10 Feb 2017.